November 25, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Issue: November/December 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Phase 1, interventional, open-label study of GAP T cells for patients with GPC3-positive liver cancers.
